At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 14, 2026 at 20:10 ET
Mesoblast announced an exclusive worldwide license to a patented CAR-MSC technology platform from Mayo Clinic, acquired via issuance of ASX ordinary shares. The deal enhances Mesoblast's cell therapy pipeline with potential for improved targeting in inflammatory diseases like ulcerative colitis, Crohn’s, and lupus nephritis.
- Mesoblast acquired exclusive worldwide rights to a CAR-MSC technology platform developed at Mayo Clinic.
- The acquisition was made through issuance of ASX ordinary shares (no cash outlay disclosed).
- Technology aims to enhance MSC homing and potency in inflammatory and autoimmune diseases, including bowel diseases and lupus nephritis.
- Mayo Clinic will provide in-kind support, including GMP manufacturing assistance.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access